Tag Archives: PAH

November, 2018

October, 2018

September, 2018

August, 2018

January, 2018

September, 2017

July, 2017

  • 12 July

    Arena Pharmaceuticals’ Ralinepag Demonstrates Positive Results in Mid-Stage PAH Study

    SAN DIEGO, July 10, 2017 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH).  In this 61-patient study, the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in …

June, 2017

October, 2016

March, 2016